Home > Healthcare > Drug Device Combination > Drug Filled Devices > Hormone Replacement Therapy Market

Hormone Replacement Therapy Market Share

Report ID: GMI6554
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Hormone Replacement Therapy Market Share

The key players in the hormone replacement therapy market are

Eli Lilly and Company
Bayer AG
Pfizer, Inc
Viatris, Inc.
Noven Pharmaceuticals, Inc.
Merck & Co., Inc.
Novo Nordisk A/S
AbbVie, Inc.
F. Hoffmann-La Roche Ltd.
ASCEND Therapeutics US, LLC.
Abbott Laboratories
Genentech Inc.
Teva Pharmaceutical Industries Ltd.
Novartis AG

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for hormone replacement therapy accounted for USD 21.8 billion in 2022 and is estimated to surpass USD 40 billion by 2032, backed by the increasing geriatric population, rising awareness of post-menopausal issues, and rising prevalence of hormonal disorders.

The estrogen & progesterone replacement therapy market segment was worth USD 11.9 billion in 2022. They are primarily used to manage the symptoms of menopause, such as hot flashes, night sweats, and mood changes.

North America dominated the market in 2022 with a revenue share of 40.2%, owing to the rising prevalence of menopause and growth hormone deficiency disorders, increasing awareness related to post-menopause issues, and presence of key players in the region.

Merck & Co., Inc., Novo Nordisk A/S, AbbVie, Inc., F. Hoffmann-La Roche Ltd., ASCEND Therapeutics US, LLC., Abbott Laboratories, Genentech Inc., Teva Pharmaceutical Industries Ltd., and Novartis AG